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Abstract Previously we reported that the R73A and H144Q
variants of the yeast cyclophilin Cpr3 were virtually inactive in a
protease-coupled peptide assay, but retained activity as catalysts
of a proline-limited protein folding reaction [Scholz, C. et al.
(1997) FEBS Lett. 414, 69^73]. A reinvestigation revealed that
in fact these two mutations strongly decrease the prolyl
isomerase activity of Cpr3 in both the peptide and the protein-
folding assay. The high folding activities found previously
originated from a contamination of the recombinant Cpr3
proteins with the Escherichia coli protein SlyD, a prolyl
isomerase that co-purifies with His-tagged proteins. SlyD is
inactive in the peptide assay, but highly active in the protein-
folding assay.
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1. Introduction
Cyclophilins catalyze the cis/trans isomerizations of prolyl
peptide bonds and bind tightly to cyclosporin A (CsA), which
inhibits this activity in a competitive manner [1^3]. Prolyl
isomerization can be a rate-limiting reaction in protein folding
[4]. Previously we reported that two variants of the yeast
mitochondrial cyclophilin Cpr3 with substitutions close to
the prolyl isomerase active site (R73A and H144Q) are virtu-
ally inactive towards a tetrapeptide substrate in a protease-
coupled activity assay, but show high residual activities as
catalysts of a proline-limited1 protein folding reaction [5,6].
A reinvestigation of the enzymatic properties of the wild-type
and mutated forms now shows that the R73A and H144Q
mutations strongly decrease the activity of Cpr3 in both the
peptide and the protein-folding assay. The high folding activ-
ities found in the previous work originated from a contami-
nation of the recombinant Cpr3 proteins with the Escherichia
coli protein SlyD. This protein co-puri¢es with His-tagged
proteins [7] and shows an extremely high prolyl isomerase
activity in the protein-folding assay, but not in the chymo-
trypsin-coupled peptide assay.
2. Materials and methods
(S54G,P55N)-RNase T1 was puri¢ed and carboxymethylated as
described [8]. The concentrations of RCM-(S54G/P55N)-RNase T1
were determined spectrophotometrically using an absorption coe⁄-
cient of O278 = 21 060 M31 cm31 [9]. The concentrations of wild-type
and mutant Cpr3 and of SlyD were determined spectrophotometri-
cally using O280 values of 16 800 M31 cm31 and 5480 M31 s31, re-
spectively.
The R73A and H144Q mutations in the mitochondrial cyclophilin
Cpr3 of yeast are analogous to the R55A and H126Q mutations in
human cyclophilin A, respectively [10]. They were engineered and
cloned in the bacterial His6 expression plasmid pTrcHisB (Invitrogen,
San Diego, CA, USA), as described [6]. The wild-type and the mutant
proteins lack the mitochondrial leader sequence but carry a hexahis-
tidine tag and a cleavage site for enterokinase at the amino-terminus.
Three hours after induction, Cpr3-producing cells were harvested
by centrifugation (10 000Ug, 20 min). The pellet was resuspended in
50 mM Tris-HCl, pH 7.9, 250 mM NaCl, 10 mM L-mercaptoethanol
and 8 mM imidazole (5 ml/g of cell pellet). To minimize proteolysis,
Complete, a mixture of protease inhibitors (Boehringer, Mannheim,
Germany), was added to the suspension. Cells were lysed by sonica-
tion, and the lysate was cleared by centrifugation (10 000Ug, 20 min,
4‡C). The supernatant was removed, ¢ltered (Qia¢lter MaxiCartridge
from Qiagen, Hilden, Germany) and applied to a Ni-NTA Super£ow
column (Qiagen, Hilden, Germany) with a £ow rate of 1 ml/min.
Bound proteins were washed with v300 ml of the lysis bu¡er and
then eluted by 50 ml 1.0 M imidazole bu¡ered in 50 mM Tris-HCl,
pH 7.9. Protein-containing fractions were pooled, dialyzed against
20 mM HEPES pH 7.5 and applied on a TMAE anion exchange
column equilibrated with the same bu¡er. The column was washed
with at least ¢ve volumes of column bu¡er. Cpr3 and SlyD could be
separated by applying a linear gradient from 0 to 1.0 M NaCl in
300 ml 20 mM HEPES pH 7.5. Cpr3 eluted at 0.25 M NaCl, SlyD
at 0.5 M NaCl. Protein-containing fractions were analyzed by the
£uorescence emission of Tyr at 305 nm and of Trp at 350 nm, after
excitation at 280 nm, and assayed for prolyl isomerase activity (see
below). Only Cpr3 contains Trp residues. The Cpr3- and SlyD-con-
taining fractions were separately puri¢ed further by size exclusion
chromatography on a Superdex 75 HiLoad column (Amersham-Phar-
macia, Uppsala, Sweden). The eluting proteins were assayed for prolyl
isomerase activity in the RCM-(S54G/P55N)-RNase T1 folding assay.
Both the Cpr3 proteins and SlyD showed purities higher than 95% as
judged by denaturing gel electrophoresis and Coomassie staining.
The chromogenic peptide succinyl-Ala-Ala-Pro-Phe-4-nitroanilide
and chymotrypsin were used in the protease-coupled assay [1,11] as
described in [5]. In the protein folding assays RCM-(S54G/P55N)-
RNase T1 was used as the substrate. These assays were performed
as described in [5]. Fluorescence was measured in a Hitachi F4010
£uorescence spectrophotometer.
The speci¢city constants kcat/KM of the prolyl isomerases in the
various assays were determined by measuring the rate constants of
the spontaneous isomerization, ko, and of catalyzed isomerization,
kobs, as a function of the enzyme concentration at substrate concen-
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trations much smaller than KM. Under these conditions kcat/KM is
derived from the dependence of kobs on enzyme concentration.
To measure CsA binding 0.9 ml of 0.1 WM wild-type or mutant
Cpr3 in 0.1 M Tris-HCl pH 8.0 was placed in the thermostatted
£uorimeter cell and titrated with CsA at 15‡C. The initial additions
were made with a 5 WM, followed by a 50 WM and ¢nally a 500 WM
CsA solution in 50% ethanol. The total volume added during the
titrations was less than 25 Wl. Control titrations showed that equal
volumes of 50% ethanol did not signi¢cantly a¡ect the £uorescence of
the Cpr3 proteins. The extent of complex formation was determined
from the increase in £uorescence emission at 340 nm (10 nm band-
width) upon excitation at 290 nm (3.0 nm bandwidth) using a Hitachi
F4010 £uorescence spectrometer. After each addition of CsA the sys-
tem was equilibrated for at least 2 min. The binding curves were
analyzed on the assumption that binding of CsA to Cpr3 is reversible.
Circular dichroism (CD) spectra of the Cpr3 proteins were meas-
ured with a Jasco J600A spectropolarimeter. Protein concentrations
were 5.0 WM in 20 mM Na phosphate bu¡er, pH 7.0 at 20‡C. The
spectra were recorded in 0.1 cm cells with a speed of 20 nm/min, a
response time of 2 s and a bandwidth of 2 nm. The spectra were
measured eight times and averaged.
3. Results and discussion
The Cpr3 proteins and SlyD co-eluted from the Ni-NTA
column. They were separated by anion exchange chromatog-
raphy over a TMAE column and further puri¢ed by gel chro-
matography. Residual SlyD could not be detected in the Cpr3
samples by SDS-PAGE. We did not succeed in removing the
His tag from the recombinant Cpr3 proteins by incubation
with enterokinase, probably because the cleavage sites were
not accessible in the fusion proteins. Therefore all compara-
tive work was performed with the Cpr3 proteins carrying an
N-terminal extension of 31 amino acids.
Wild-type Cpr3 and the R73A and H144Q variants are
stably folded proteins and show virtually identical CD spectra
in the amide region (data not shown). Binding of CsA to
cyclophilins leads to an increase of the intrinsic tryptophan
£uorescence [2]. When 10 WM CsA was added to 1 WM Cpr3,
the £uorescence intensities of the wild-type protein, the R73A
and the H144Q variants increased by 35, 30, and 45%, respec-
tively, which indicates that they interact with CsA. The a⁄n-
ity for CsA was, however, strongly reduced (by about two
orders of magnitude) by the R73A and H144Q mutations.
The apparent dissociation constants as derived from £uores-
cence titrations are 910 nM for wild-type Cpr3, 0.30 WM for
the R73A, and 0.25 WM for the H144Q variant (Table 1). This
agrees well with the ¢nding that these variants do not bind
appreciably to CsA in a drug binding assay [6].
The catalytic activities of the three proteins as measured by
the chymotrypsin-coupled peptide assay are shown in Table 1.
This assay is based on the conformational speci¢city of chy-
motrypsin, which cleaves the peptide Suc-Ala-Ala-Pro-Phe-4-
nitroanilide only when the Xaa-Pro bond is trans. Puri¢ed
wild-type Cpr3 shows a kcat/KM value of 5.8U106 M31 s31,
which resembles the kcat/KM values that were found previously
for other cyclophilins [3,12]. The activities of both variants are
strongly reduced to levels below 1% of the activity of the wild-
type protein (Table 1). These residual activities are fully in-
hibited by 4.5 WM CsA, which shows that they do not origi-
nate from E. coli prolyl isomerases of the FKBP or parvulin
type. Neither are they likely to originate from the E. coli
cyclophilins, because those are only weakly inhibited by
5 WM CsA [13,14]. CsA binds to wild-type Cpr3 with a very
high a⁄nity (Table 1) and accordingly inhibits its prolyl iso-
merase activity with an inhibition constant of 3.8U1039 M
(data not shown). The activities of the wild-type form and the
two variants of Cpr3 decrease only slightly when they are
incubated with 30 WM chymotrypsin for 10 min (Table 1).
SlyD, however, is hydrolyzed very rapidly by this protease
and is thus inactive in the chymotrypsin-coupled assay (Table
1 and [15,16]).
The activities of the Cpr3 proteins and of SlyD as catalysts
of a proline-limited protein folding reaction were measured as
before by using the reduced and carboxymethylated form of
S54G/P55N-RNase T1 as a substrate protein. Its refolding is
limited in rate by the transCcis isomerization of the Tyr38-
Pro39 bond. In this folding assay wild-type Cpr3 showed a
kcat/KM value of about 70 000 M31 s31 (Table 2), which is
similar to the activities of other cyclophilins in this assay.
This activity is completely inhibited by 4.5 WM CsA.
In the protein-folding assay the catalytic activities of the
two Cpr3 variants are strongly reduced as well. The R73A
variant shows a kcat/KM value of about 1000 M31 s31, which,
in the presence of 4.5 WM CsA, is reduced to about 700 M31
s31. The kcat/KM value for the H144Q variant is about
550 M31 s31 in the absence of CsA. In the presence of
4.5 WM CsA H144Q-Cpr3 is inactive. This shows that the
variants show about 0.5% of the folding activity of the wild-
type protein. The H144Q variant seems to be extremely pure,
the R73A variant still contains a very small amount of SlyD.
SlyD is a member of the FKBP family but is not inhibited by
FK 506. It shows an enormous activity in the folding assay
(see below).
Together, the results in Tables 1 and 2 indicate that both
mutations are strongly inactivating, and that, contrary to our
previous results [5,6], the inactivation is re£ected in both the
peptide and protein-folding assays. The extent of inactivation
is similar to the inactivations of human cyclophilin A by the
analogous mutations [10].
SlyD is rapidly hydrolyzed by chymotrypsin and is there-
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Table 1
Activities of wild-type Cpr3, its R73A and H144Q variants and of SlyD in the protease-coupled peptide assaya
Species kcat/KM
(M31 s31)
Activity relative to
wild-type Cpr3 (%)
kcat/KM after 10 min incubation
with 30 WM chymotrypsin (M31 s31)
Inhibition by
4.5 WM CsA
KD of complex
with CsAb
Wild-type Cpr3 5.8U106 100 5.6U106 yes 9 10 nM
R73A-Cpr3 6 700 0.11 5 100 yes 0.30 WM
H144Q-Cpr3 16 700 0.28 13 500 yes 0.25 WM
SlyD 9 500 9 0.008 9 500 ^ ^
aThe activities were measured using the peptide succinyl-Ala-Ala-Pro-Phe-4-nitroanilide and the chymotrypsin-coupled assay in 0.1 M Tris-HCl,
pH 8.0 at 15‡C. The protein concentrations were 10 nM (wild-type Cpr3), 200 nM (R73A- and H144Q-Cpr3), and 200 nM (SlyD). The
uncertainties in the activity measurements are þ 0.2U106 M31 s31 for wild-type Cpr3 and þ 2000 M31 s31 for the Cpr3 mutants.
bThe dissociation constants KD of the complexes with CsA were determined by £uorescence titrations in 0.1 M Tris-HCl, pH 8.0 at 15‡C as
described in Section 2.
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fore inactive in the peptide assay. In the protein-folding assay,
however, it shows a remarkably high activity, and, under the
conditions used, it reaches a kcat/KM value of about 450 000
M31 s31. This is 6^7-fold higher than the corresponding ac-
tivity of wild-type Cpr3 (Table 2). SlyD is a prolyl isomerase
of the FKBP type, but its high activity in the folding assay is
hardly a¡ected by 3.0 WM FK 506. Using a trypsin-coupled
peptide-based assay Hottenrott et al. also found that SlyD
was insensitive to inhibition by FK 506 [15].
The very high activity of SlyD in the protein-folding assay,
the lack of activity in the chymotrypsin-coupled peptide assay,
the fact that Cpr3 and SlyD have similar molecular weights,
and the insensitivity of SlyD to FK 506 inhibition explain in
large part our previous erroneous results [5,6]. In those experi-
ments the contaminating SlyD did not contribute to the activ-
ities measured by the chymotrypsin-coupled peptide assay,
because it was inactivated by the protease. It did, however,
contribute strongly to the activity measured in the protein-
folding assay, because in this assay SlyD is much more active
than Cpr3. The insensitivity to inhibition by FK 506 was
previously taken as evidence that the measured high folding
activities of the Cpr3 proteins originated from a cyclophilin
and not from an E. coli FKBP. However, SlyD binds FK 506
so weakly that it is not signi¢cantly inhibited by FK 506. In
addition, SlyD contains no Trp residues and thus in the orig-
inal samples contributed very little to the absorbance, which
was used to determine the prolyl isomerase concentrations.
Together, our results indicate that Cpr3 resembles human
cyclophilin A [10] in its sensitivity to mutations of a His and
an Arg residue in the active site region. In contrast to our
previous conclusions [5,6], these two mutations reduce the
activities towards both peptide and protein substrates in a
similar manner to less than 1% of the activity of the wild-
type protein. These results are now in accord with the con-
clusion that Arg55 is a catalytic residue, as drawn from the
crystal structure of human cyclophilin A complexed with a
peptide [17]. The H144Q mutation in Cpr3 does not a¡ect
the folding of an imported protein in mitochondria derived
from a mutant yeast strain, and the viability of this strain on
lactate at 37‡C is also not a¡ected [6]. Thus, either the resid-
ual in vitro activity of the puri¢ed H144Q variant of Cpr3 is
su⁄cient to explain the absence of e¡ects in vivo and in mi-
tochondria, or prolyl isomerase activity is dispensable for the
in vivo activity of Cpr3. Finally, these ¢ndings for the Cpr3
active site mutants may also be relevant to our related studies
of FKBP12 active site mutants [6], which will also be re-in-
vestigated.
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Table 2
Activities of wild-type Cpr3, its R73A and H144Q variants and of SlyD in the protein-folding assaya
Species kcat/KM
(M31 s31)
kcat/KM in the presence
of 4.5 WM CsA (M31 s31)
Activity relative to
wild-type Cpr3 (%)
kcat/KM in the presence of
3.5 WM FK 506 (M31 s31)
Wild-type Cpr3 70 000 9 1 000 100 70 000
R73A-Cpr3 1 000 700 0.4 950
H144Q-Cpr3 550 9 100 0.7 550
SlyD 450 000 450 000 640 420 000
aThe activities were measured by using RCM-(S54G/P55N)-RNase T1 as the refolding protein substrate. Folding was measured in 0.1 M Tris-HCl,
pH 8.0 at 15‡C. The protein concentrations were 200 nM (wild-type Cpr3), 1 WM (R73A- and H144Q-Cpr3), and 10 nM (SlyD). The uncertainties
in the activity measurements are þ 1000 M31 s31 for wild-type Cpr3 and SlyD and þ 100 M31 s31 for the Cpr3 mutants.
C. Scholz et al./FEBS Letters 443 (1999) 367^369 369
